Project Grant K99CA296729
Award Date
3/1/25
Completion Date
2/28/27
Dollars Obligated
$114K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to advance the understanding of "tissue-resident adaptive CD56bright NK cell responses in cancer". The primary objectives are to determine the role of CD56bright NK cell populations, referred to as "Bright-Tanks", in recruiting anti-tumor immune cells, and to identify transcription factors that promote tissue-resident and adaptive phenotypes in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports scientific research aimed at understanding the fundamental biological mechanisms underlying cancer development and potential treatment interventions. The $470,464 award to the Regents of the University of Minnesota will fund a 5-year study to investigate the allosteric mechanisms that drive paradoxical activation of RAF kinases, which are key drivers of melanoma, thyroid, and colon...
The National Cancer Institute (NCI) awarded a $340,822 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Mayo Clinic in Rochester, Minnesota. The grant, with a period of performance from July 26, 2024 to March 31, 2026, will support research to investigate the role of the DUSP2 gene in regulating cytotoxic CD8+ T cell responses to immune checkpoint blockade (ICB) cancer therapies. The goal is to uncover the mechanisms by which DUSP2 expression in CD8+ T cells negatively...
The National Cancer Institute (NCI) awarded a $293,369 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Duke University. The grant supports research to investigate the mechanisms by which residual tumor cells evade the immune system following treatment with oncogene-targeted therapies. The research aims to uncover potential targets to enhance the immune-mediated clearance of these resistant tumor cells, which often serve as a reservoir for cancer relapse. Key focus areas...
This $108,512 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by Emory University to investigate the role of the ICOS signaling pathway in improving the durability and persistence of anti-tumor T cells for cancer immunotherapy. The research aims to: 1) Examine how ICOS inhibition affects the formation of resident memory T cells in the context of immune checkpoint blockade and adoptive T cell transfer, and 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $499,744.00 to the Regents of the University of Minnesota to conduct research on the role of the STAT5 signaling pathway in tumor-associated macrophages and its impact on breast cancer growth and metastasis. The key objectives are to: 1) define the effects of deleting the STAT5 gene in macrophages on mammary tumor progression, 2) identify the mechanisms by which STAT5 modulation in...
The National Cancer Institute (NCI) awarded a $509,448 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Leland Stanford Junior University. The grant aims to delineate the antigen-presenting cell population responsible for mediating tumor-specific regulatory T cell induction and to develop immunotherapeutic strategies to overcome metastatic cancer. Specifically, the project will use high-dimensional imaging, single-cell RNA sequencing, in vivo cell depletion models,...
This Project Grant award of $176,712 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pittsburgh to investigate mechanisms of cancer immunosurveillance. The research aims to develop a new mouse model to evaluate the role of the CD91 receptor on antigen presenting cells in priming T cell responses against emerging tumors. Specifically, the project will explore how tumor-derived heat shock proteins delivered through the CD91...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research aimed at improving engineered TCR-T cell therapy for solid tumors. The research focuses on understanding why engineered TCR-T cells form a different type of stem-like reservoir in tumor-draining lymph nodes compared to endogenous tumor-specific T cells. The project also evaluates whether this...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $101,856 to The Trustees of Columbia University in the City of New York to conduct research aimed at understanding how genetic variants impact the anti-tumor activity of T cells. The funded project will: Define the mechanisms by which specific PIK3CD genetic variants modulate T cell function and evaluate their in vivo impact in murine models of melanoma and leukemia...